22 results found.

Brain and Central Nervous System Tumors, Cognitive/Functional Eff Clinical Trial using modafinil; placebo

University of South Florida - Recruiting 6 years to 17 years.
- A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor.
modafinil; placebo

Brain and Central Nervous System Tumors, Intraocular Melanoma, Lu Clinical Trial using DNA analysis; immunologic technique; pharmacological study; iodine I 131 monoclonal antibody 3F8; 131I-3F8

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms.
DNA analysis; immunologic technique; pharmacological study; iodine I 131 monoclonal antibody 3F8; 131I-3F8

Astrocytoma, Central Nervous System Tumor, Glioblastoma, Glioma, Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 1 year or older.
- Evaluation of the Natural History of Patients With Tumors of the Central Nervous System.

Brain and Central Nervous System Tumors Clinical Trial

St. Jude Children's Research Hospital - Recruiting N/A to 21 years.
- Molecular and Histopathologic Characterization of Atypical Teratoid Rhabdoid Tumors, Choroid Plexus Carcinomas, Ependymomas and Medulloblastoma/PNET of the Pediatric CNS.

Brain and Central Nervous System Tumors Clinical Trial using polymorphism analysis; laboratory biomarker analysis; medical chart review

University of California, San Francisco - Recruiting 18 years or older.
- San Francisco Bay Area Adult Glioma Prognosis Study Protocol.
polymorphism analysis; laboratory biomarker analysis; medical chart review

Brain and Central Nervous System Tumors Clinical Trial using mibefradil dihydrochloride; temozolomide; 3'-deoxy-3'-[18F]fluorothymidine; pharmacological study

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment.
mibefradil dihydrochloride; temozolomide; 3'-deoxy-3'-[18F]fluorothymidine; pharmacological study

Primary Brain Tumors, or Secondary Brain Tumors Clinical Trial using 4-Demethyl-4-cholestryloxycarbonylpenclomedine

DEKK-TEC, Inc. - Recruiting 18 years or older.
- A Phase II Trial: Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Malignancies Involving the Central Nervous System.
4-Demethyl-4-cholestryloxycarbonylpenclomedine

Brain and Central Nervous System Tumors Clinical Trial using carboplatin; tamoxifen citrate; temozolomide; adjuvant therapy; radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas.
carboplatin; tamoxifen citrate; temozolomide; adjuvant therapy; radiation therapy

Brain and Central Nervous System Tumors, Neuroblastoma, or Sarcom Clinical Trial using iodine I 131 monoclonal antibody 8H9

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Phase I Study Of Intrathecal Radioimmunotherapy Using I-8H9 For Central Nervous System/Leptomeningeal Neoplasms.
iodine I 131 monoclonal antibody 8H9

Brain and Central Nervous System Tumors Clinical Trial using olaparib; temozolomide; gene expression analysis; protein expression analysis; laboratory biomarker analysis; pharmacological study; diffusion-weighted magnetic resonance imaging; dynamic contrast-enhanced magnetic resonance imaging; therapeutic conventional surgery

Cancer Research UK - Recruiting 18 years to 70 years.
- A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma.
olaparib; temozolomide; gene expression analysis; protein expression analysis; laboratory biomarker analysis; pharmacological study; diffusion-weighted magnetic resonance imaging; dynamic contrast-enhanced magnetic resonance imaging; therapeutic conventional surgery

Brain and Central Nervous System Tumors, Chronic Myeloproliferati Clinical Trial using 3'-deoxy-3'-[18F]fluorothymidine

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years or older.
- Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET).
3'-deoxy-3'-[18F]fluorothymidine

Brain and Central Nervous System Tumors Clinical Trial using hydroxyurea; imatinib mesylate

National Cancer Institute (NCI) - Recruiting 18 years to 75 years.
- IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study.
hydroxyurea; imatinib mesylate

Primary Central Nervous System Lymphoma, Brain and Central Nervou Clinical Trial using Rituxan; Carboplatin; Methotrexate; Sodium thiosulfate; Neupogen; Neulasta; Leucovorin

OHSU Knight Cancer Institute - Recruiting 18 years to 75 years.
- A Phase I/II Study of Patient With Newly Diagnosed Primary Central Nervous System Lymphoma Treated With Methotrexate/BBBD, and Adding Rituximab (an Anti CD-20 Antibody) and Carboplatin, to the Treatment Regimen.
Rituxan; Carboplatin; Methotrexate; Sodium thiosulfate; Neupogen; Neulasta; Leucovorin

Central Nervous System (CNS) Metastases, or Brain Metastases Clinical Trial using Topotecan; Temozolomide

The Methodist Hospital System - Recruiting 18 years to 79 years.
- Phase II Trial of Chemotherapy With Temozolomide in Combination With Topotecan for Central Nervous System (CNS) Metastasis of Solid Tumors.
Topotecan; Temozolomide

Brain and Central Nervous System Tumors Clinical Trial using dasatinib; temozolomide; placebo

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined With Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM).
dasatinib; temozolomide; placebo

Brain and Central Nervous System Tumors Clinical Trial using biologic sample preservation procedure

National Cancer Institute (NCI) - Recruiting N/A to 18 years.
- A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens.
biologic sample preservation procedure

Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Clinical Trial using crizotinib; pharmacogenomic studies; pharmacological study

National Cancer Institute (NCI) - Recruiting 1 year to 21 years.
- A Phase I/II Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-Met, in Children With Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma.
crizotinib; pharmacogenomic studies; pharmacological study

Brain and Central Nervous System Tumors Clinical Trial using cisplatin; cyclophosphamide; etoposide; lomustine; vincristine sulfate

National Cancer Institute (NCI) - Recruiting 3 years to 30 years.
- Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma).
cisplatin; cyclophosphamide; etoposide; lomustine; vincristine sulfate

Brain and Central Nervous System Tumors Clinical Trial using temozolomide; DNA methylation analysis; laboratory biomarker analysis; adjuvant therapy; quality-of-life assessment; radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial..
temozolomide; DNA methylation analysis; laboratory biomarker analysis; adjuvant therapy; quality-of-life assessment; radiation therapy

Brain and Central Nervous System Tumors Clinical Trial using antineoplaston A10; antineoplaston AS2-1

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma.
antineoplaston A10; antineoplaston AS2-1

Brain and Central Nervous System Tumors Clinical Trial using antineoplaston A10; antineoplaston AS2-1

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Primary Malignant Brain Tumors.
antineoplaston A10; antineoplaston AS2-1

Brain and Central Nervous System Tumors Clinical Trial using adjuvant therapy; radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years to 70 years.
- Adjuvant Postoperative High-Dose Radiotherapy for Atypical and Malignant Meningioma: a Phase-II and Observation Study.
adjuvant therapy; radiation therapy